|
HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry.
In its global offering, Ribo issued a total of 31,610,400 shares at an offer price of HKD 57.97 per share, raising gross proceeds of over 1.8 billion Hong Kong dollars, HKPO was over 100x oversubscribed, International Placing was 16.7x oversubscribed, reflecting strong global investor confidence in the value of the siRNA sector and the Company's capabilities. The IPO proceeds will provide solid financial support for the advancement of the Company's core business. In addition, the offering attracted 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International and Dacheng Fund, and Taikang Life Insurance etc., demonstrating the strong confidence of leading institutions in the Company's long-term prospects.
Dr. Zicai Liang, Founder, Chairman and Chief Executive Officer of Ribo, commented: "Listing on the Hong Kong Stock Exchange represents a major milestone in Ribo's journey. We extend our sincere gratitude to global investors for their trust and support. Moving forward, we will leverage the international capital markets to accelerate the global clinical development and commercialization of siRNA therapeutics, further strengthen our technologies, deliver breakthrough therapies to patients worldwide while creating sustainable value for shareholders."
Proceeds from the offering will be allocated across four key areas: (1) Advancing global multicenter clinical trials for core products; (2) Supporting preclinical and clinical development of the pipeline; (3) Iterating and upgrading siRNA delivery and other technology platforms; (4) Replenishing operational capital and earmarking funds for routine corporate purposes.
Ribo has built a fully integrated R&D platform with independent intellectual property rights. Its innovative liver-targeting RiboGalSTARTM delivery technology has successfully advanced multiple products into Phase II clinical trials. The Company has established R&D centers in Suzhou, Beijing and Gothenburg, Sweden, and a global R&D network capable of supporting end-to-end drug development from discovery to global clinical trials.
The listing was jointly sponsored by China International Capital Corporation and Citigroup, which provided professional support for the Company's successful entry into the capital markets.
About Ribo Life Science
Suzhou Ribo Life Science Co., Ltd. (06938.HK) is a global biopharmaceutical company engaged in the development and commercialization of small interfering RNA (siRNA) therapeutics. Powered by its proprietary and innovative siRNA technology platforms, the Company has built a rich and differentiated pipeline targeting major disease areas including cardiovascular, metabolic, liver and kidney diseases. Ribo is committed to delivering revolutionary treatment solutions to patients worldwide through continuous innovation.
For more information, please visit: www.ribolia.com.
HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry.
In its global offering, Ribo issued a total of 31,610,400 shares at an offer price of HKD 57.97 per share, raising gross proceeds of over 1.8 billion Hong Kong dollars, HKPO was over 100x oversubscribed, International Placing was 16.7x oversubscribed, reflecting strong global investor confidence in the value of the siRNA sector and the Company's capabilities. The IPO proceeds will provide solid financial support for the advancement of the Company's core business. In addition, the offering attracted 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International and Dacheng Fund, and Taikang Life Insurance etc., demonstrating the strong confidence of leading institutions in the Company's long-term prospects.
Dr. Zicai Liang, Founder, Chairman and Chief Executive Officer of Ribo, commented: "Listing on the Hong Kong Stock Exchange represents a major milestone in Ribo's journey. We extend our sincere gratitude to global investors for their trust and support. Moving forward, we will leverage the international capital markets to accelerate the global clinical development and commercialization of siRNA therapeutics, further strengthen our technologies, deliver breakthrough therapies to patients worldwide while creating sustainable value for shareholders."
Proceeds from the offering will be allocated across four key areas: (1) Advancing global multicenter clinical trials for core products; (2) Supporting preclinical and clinical development of the pipeline; (3) Iterating and upgrading siRNA delivery and other technology platforms; (4) Replenishing operational capital and earmarking funds for routine corporate purposes.
Ribo has built a fully integrated R&D platform with independent intellectual property rights. Its innovative liver-targeting RiboGalSTARTM delivery technology has successfully advanced multiple products into Phase II clinical trials. The Company has established R&D centers in Suzhou, Beijing and Gothenburg, Sweden, and a global R&D network capable of supporting end-to-end drug development from discovery to global clinical trials.
The listing was jointly sponsored by China International Capital Corporation and Citigroup, which provided professional support for the Company's successful entry into the capital markets.
About Ribo Life Science
Suzhou Ribo Life Science Co., Ltd. (06938.HK) is a global biopharmaceutical company engaged in the development and commercialization of small interfering RNA (siRNA) therapeutics. Powered by its proprietary and innovative siRNA technology platforms, the Company has built a rich and differentiated pipeline targeting major disease areas including cardiovascular, metabolic, liver and kidney diseases. Ribo is committed to delivering revolutionary treatment solutions to patients worldwide through continuous innovation.
For more information, please visit: www.ribolia.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
LAS VEGAS, Jan. 9, 2026 /PRNewswire/ -- Guide Sensmart (Booth 21740, Central Hall), a global leader in thermal imaging technology, officially launched its next-generation thermal imaging innovation – ApexVision – alongside a series of new products empowered by the technology. This launch represents a systemic leap for the industry from merely "seeing heat" to "seeing with clarity, precision, and intelligence," marking the dawn of a new era defined by Ultra-Clarity.
CES Show Floor Reaction: "Ultra-Clarity" Draws Deep Engagement
At the Guide Sensmart booth, live product demonstrations powered by ApexVision attracted strong attention from industry analysts to global media. Hands-on comparisons—such as maintaining clear imaging details of distant targets and delivering crisp, smear-free imaging of fast-moving objects—earned consistent praise. Many professional visitors noted that this reliable "what-you-see-is-what-you-get" clarity would directly enhance operational efficiency and decision-making confidence.
ApexVision integrating both hardware and software: It combines the high-sensitivity ApexCore S1 detector, the Nexus 1.0 processing platform, and scenario-optimized algorithms. Together, ApexVision successfully overcomes persistent challenges such as low contrast in complex environments, detail loss at long range or high magnification, motion blur on fast-moving objects, and inaccurate detection of minute temperature differences.
From Architecture to Application: A Full Portfolio Empowered
On the CES show floor, Guide Sensmart demonstrated how ApexVision delivers tangible improvements across thermal devices. Thermography tools (e.g. E3S, H6S thermal cameras) leverage the SharpIR 2.0 algorithm to provide stable, accurate temperature measurement in demanding environments, enabling inspectors to pinpoint hidden faults with greater confidence. Outdoor hunting optics (e.g. TD650LS monocular and TN650MS binocular), benefit from Hyper-Light 2.0, allowing users to identify nocturnal wildlife in complete darkness and track fast-moving targets while maintaining clean, sharp images even at 10× zoom.
"The launch of ApexVision marks a milestone where our vertically integrated technology development translates into real value for users," said a Guide Sensmart spokesperson. "It is more than a set of specifications—it delivers the certainty of Ultra-Clarity to every professional user."
The debut of ApexVision at CES 2026 signifies more than a routine product update. By resolving long-standing trade-offs between sensitivity, stability, and environmental robustness, Guide Sensmart is advancing thermal imaging into the Ultra-Clarity Era, building a clearer, safer, and more efficient future.
We are keen to explore partnership of collaboration with you. Know more about Guide Sensmart at https://www.guideir.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ApexVision Debuts at CES 2026: Guide Sensmart Ushers in the Ultra-Clarity Era of Thermal Imaging
